On June 14, 2024, the U.S. FDA approved AstraZeneca’s Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.
FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer
- Post author:
- Post published:August 5, 2024
- Post category:uncategorized